Dr. Richard Isaacson was featured by CNN following the FDA clearance of Roche’s Elecsys pTau181 blood test, the first blood-based biomarker test approved for use in primary care to help rule out Alzheimer’s-related amyloid pathology. The article explores how this new diagnostic tool could expand access to earlier evaluation while emphasizing that blood tests are one part of a comprehensive diagnostic process—not a standalone diagnosis.

Dr. Isaacson highlighted the significance of the FDA’s decision while underscoring the need for careful clinical interpretation:

“This is another major step forward in making Alzheimer’s biomarker testing more accessible, but blood test results should always be considered alongside a patient’s symptoms, medical history, cognitive evaluation, and other clinical findings.”

Read the full CNN article to learn more about how FDA-cleared blood tests are helping reshape the future of Alzheimer’s detection and care.